Kidney hope: drug combo may slow alport disease
NCT ID NCT06499948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 trial tested two drugs—dapagliflozin and spironolactone—alone and together in 12 adults with Alport syndrome, a genetic kidney disease. The goal was to see if these drugs could lower protein levels in urine, a key sign of kidney damage. Participants took each drug for 4 weeks, then both together, while continuing standard care. The study aims to find a way to delay kidney failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin and Spironolactone
What this could lead to
If successful, this could point toward a new way to slow kidney disease progression in Alport syndrome by lowering protein in the urine.
What could go wrong
This is a very small, early-phase trial (12 people) with short treatment periods. Results may not apply to all patients, and the drugs may not show lasting benefit or could cause side effects like high potassium.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundeni Clinical Institute
Bucharest, Sector 2, 020021, Romania